Source comparison
CJC-1295 No DAC vs Ipamorelin: Which Better Comparison — Comparison Table
Before selecting a peptide, researchers must align mechanism, kinetics, and practical administration requirements with study objectives. The table below distills the key differentiators. Mechanism GHRH analog; binds GHRH receptors on pituitary somatotrophs Ghr
This comparison does not assign a generated winner or score.
- Before selecting a peptide, researchers must align mechanism, kinetics, and practical administration requirements with study objectives. The table below distills the key differentiators.
- Mechanism
- GHRH analog; binds GHRH receptors on pituitary somatotrophs
- Ghrelin receptor agonist; binds GHS-R1a in hypothalamus and pituitary
- Different pathways. Can be stacked without receptor competition
- GH Release Pattern
- Sustained baseline elevation lasting 90–180 minutes
- Pulsatile GH spikes peaking at 15–30 min, resolving by 120 min
- CJC sustains; Ipamorelin pulses. Mimics natural diurnal rhythm better when combined
- Half-Life
- ~30 minutes
- ~2 hours
- Both require multiple daily doses for sustained effect
- Typical Dosing
- 100–200 mcg, 2–3× daily
- 200–300 mcg, 2–3× daily
- Stacking uses lower doses of each than solo protocols
- Side Effects
- Flushing, transient headache, injection site irritation
- Minimal; no cortisol/prolactin elevation
- Ipamorelin cleaner side effect profile than earlier GHRP analogs
- Synergy Potential
- High when paired with ghrelin mimetics
- High when paired with GHRH analogs
- Co-administration yields 3–5× GH output vs solo use